The Latest Breaking News from WST

West Pharmaceutical Services Inc (NYSE:WST) reported first-quarter FY22 sales growth of 7.4% year-on-year to $720 million, missing the consensus of $720.92 million. Proprietary products segment revenue grew 10.6% Y/Y to $601.3 million. Contact-manufactured products segment sales declined 6.6% to $118.7 million. Gross profit margin fell 100 basis points to 40%, and the gross…

  West Pharmaceutical Servs (NYSE:WST) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Despite no clarity on when the Russia-Ukraine war will end, surging inflation, and logistical hindrances, the U.S. economy looks sufficiently resilient to weather the crises. Given this backdrop, we think shares of beaten-down growth stocks IQVIA (IQV), West Pharmaceutical (WST), and Synopsys (SNPS) could soar in price in the coming…

If history is any guide, there may be trouble ahead for shares of West Pharmaceutical Servs (NYSE:WST). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.